Key Market Indicators
Sales of Norwegian antirheumatic medicine are forecast to reach $55 million by 2026. In 2021, the market was valued at $60 million. This is a decrease of 1.3% year-on-year, on average, since 2007. Norway ranked 13th in 2021, overtaken by Greece with sales of $60 million. Germany, Spain, and Canada ranked 2nd, 3rd, and 4th respectively in this ranking.
